200,000+ products from a single source!
sales@angenechem.com
51131-85-2 | 5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-ol
CAS No: 51131-85-2 Catalog No: AG00DLTH MDL No:
Product Description
Catalog Number:
AG00DLTH
Chemical Name:
5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-ol
CAS Number:
51131-85-2
IUPAC Name:
5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-ol
InChI:
InChI=1S/C17H14N2O/c1-9-14-8-18-6-5-12(14)10(2)17-16(9)13-7-11(20)3-4-15(13)19-17/h3-8,19-20H,1-2H3
InChI Key:
QZTWUDDGLIDXSE-UHFFFAOYSA-N
EC Number:
257-000-0
UNII:
9G4A3ET6XG
NSC Number:
237070
Properties
Complexity:
374
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
262.111g/mol
Formal Charge:
0
Heavy Atom Count:
20
Hydrogen Bond Acceptor Count:
2
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
262.312g/mol
Monoisotopic Mass:
262.111g/mol
Rotatable Bond Count:
0
Topological Polar Surface Area:
48.9A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.4
Literature
| Title | Journal |
|---|---|
| Old drug, new target: ellipticines selectively inhibit RNA polymerase I transcription. | The Journal of biological chemistry 20130215 |
| Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases. | Chemical research in toxicology 20120521 |
| Ellipticines and 9-acridinylamines as inhibitors of D-alanine:D-alanine ligase. | Bioorganic & medicinal chemistry 20110901 |
| Ellipticine cytotoxicity to cancer cell lines - a comparative study. | Interdisciplinary toxicology 20110601 |
| Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers. | Cell communication and signaling : CCS 20110101 |
| Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl. | FEBS letters 20090903 |
| Ellipticine and benzo(a)pyrene increase their own metabolic activation via modulation of expression and enzymatic activity of cytochromes P450 1A1 and 1A2. | Interdisciplinary toxicology 20080901 |
| Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes. | Neuro endocrinology letters 20061201 |
| Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems. | General physiology and biophysics 20060901 |
| Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. | Journal of medicinal chemistry 20051006 |
| Development of a novel cytochrome p450 bioaffinity detection system coupled online to gradient reversed-phase high-performance liquid chromatography. | Journal of biomolecular screening 20050801 |
| The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. | Cancer research 20041115 |
| 9-hydroxyellipticine and derivatives as chemotherapy agents. | Mini reviews in medicinal chemistry 20030301 |
| Identification of new drug sensitivity genes using genetic suppressor elements: protein arginine N-methyltransferase mediates cell sensitivity to DNA-damaging agents. | Cancer research 20030101 |
| Cardioprotective effects of 9-hydroxyellipticine on ischemia and reperfusion in isolated rat heart. | Japanese journal of pharmacology 20020501 |
| 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein. | Anticancer research 20010101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.